Combination Casodex® and Iressa™ in locally advanced prostate cancer
Study identifier:1839IL/0129
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomized placebo controlled study to assess the rate of PSA decrease, anatomical & metabolic changes in the prostate determined by MRI/3D-MRS & histological changes by biopsy in subjects with locally advanced prostate carcinoma treated with either Casodex® (bicalutamide) alone or the combination of Casodex® & ZD1839 (Iressa™)
Medical condition
Locally advanced prostate cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Iressa
Sex
Male
Actual Enrollment
102
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Dec 2003
Primary Completion Date: -
Study Completion Date: 01 Aug 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Norway Medical Director
AstraZeneca AS
